Objectives: Human papillomavirus (HPV) is a well-known oncogenic virus associated with anogenital carcinomas. Despite the anatomical proximity of the bladder and the anogenital region, the relationship between HPV and urothelial carcinoma of the bladder (UCB) is still a controversial issue. This study aimed to test the urethral swabs and first-void urine samples of patients with UCB for HPV-Deoxyribonucleic acid (DNA) using polymerase chain reaction (PCR) assay and to compare the results with a control group. Materials and Methods: Sixty-nine patients who were diagnosed with UCB between January and December 2018 were included in this case-control study. Sixty-nine patients who visited the urology outpatient clinic for non-oncological reasons within the study period were designated as the control group. Urethral swab and first-void morning urine samples were collected from each patient. HPV-DNA presence was investigated using a PCR kit that can detect a total of 22 HPV genotypes, of which 18 are high-risk and 3 are low-risk genotypes. Results: The mean age of the patients included in the study was 63.2 ± 12.6 years and the male to female ratio was 5.3. HPV-DNA was detected in 28.9% (20/69) of the patients in the case group and in 8.7% (6/69) of the patients in the control group. HPV-DNA positivity was significantly higher in the case group (OR 4.24; 95% CI 1.63–12.34). No statistically significant relationship was found between HPV-DNA positivity and tumor grade (p = 0.36). Conclusion: A statistically significant relationship exists between HPV infection and UCB, regardless of the tumor grade.

Keywords:
Human papillomavirus, Urothelial carcinoma of the bladder, Polymerase chain reaction
1.
Tolstov Y, Hadaschik B, Pahernik S, Hohenfellner M, Duensing S. Human papillomaviruses in urological malignancies: a critical assessment.
Urol Oncol
. 2014 Jan;32(1):46.e19–27.
2.
Cobos C, Figueroa JA, Mirandola L, Colombo M, Summers G, Figueroa A, et al. The role of human papilloma virus (HPV) infection in non-anogenital cancer and the promise of immunotherapy: a review.
Int Rev Immunol
. 2014 Oct;33(5):383–401.
3.
Heidegger I, Borena W, Pichler R. The role of human papilloma virus in urological malignancies.
Anticancer Res
. 2015 May;35(5):2513–9.
4.
de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses.
Virology
. 2004 Jun;324(1):17–27.
5.
Zeuschner P, Ueberdiek S, Pryalukhin A, Veith C, Saar M, Smola S, et al. Human Papillomavirus-Associated Invasive Condylomas in a Man with Immunosuppressive Comorbidities.
Urol Int
. 2019;102(2):238–42.
6.
Sarier M, Ozel E, Duman I, Yuksel Y, Demirbas A. HPV type 45-positive condyloma acuminata of the bladder in a renal transplant recipient.
Transpl Infect Dis
. 2017 Apr;19(2):e12667.
7.
Kraus I, Molden T, Holm R, Lie AK, Karlsen F, Kristensen GB, et al. Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas.
J Clin Microbiol
. 2006 Apr;44(4):1310–7.
8.
Assmann G, Sotlar K. HPV-assoziierte Plattenepithelkarzinogenese.
Pathologe
. 2011 Sep;32(5):391–8.
9.
Visalli G, Facciolà A, D’Aleo F, Pinzone MR, Condorelli F, Picerno I, et al. HPV and urinary bladder carcinoma: a review of the literature.
WCRJ
. 2018;5(1):1–12.
10.
Gutiérrez J, Jiménez A, de Dios Luna J, Soto MJ, Sorlózano A. Meta-analysis of studies analyzing the relationship between bladder cancer and infection by human papillomavirus.
J Urol
. 2006 Dec;176(6 Pt 1):2474–81.
11.
Schmid SC, Thümer L, Schuster T, Horn T, Kurtz F, Slotta-Huspenina J, et al. Human papilloma virus is not detectable in samples of urothelial bladder cancer in a central European population: a prospective translational study.
Infect Agent Cancer
. 2015 Sep;10(1):31.
12.
Chavan S, Bray F, Lortet-Tieulent J, Goodman M, Jemal A. International variations in bladder cancer incidence and mortality.
Eur Urol
. 2014 Jul;66(1):59–73.
13.
Ehdaie B, Sylvester R, Herr HW. Maintenance bacillus Calmette-Guérin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence.
Eur Urol
. 2013 Oct;64(4):579–85.
14.
Karim R, Meyers C, Backendorf C, et al. Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes.
PLoS One
. 2011 Mar 14;6(3):e17848.
15.
Kanodia S, Fahey LM, Kast WM. Mechanisms used by human papillomaviruses to escape the host immune response.
Curr Cancer Drug Targets
. 2007 Feb;7(1):79–89.
16.
Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, Choyke PL, et al. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan.
Nat Med
. 2007 Jul;13(7):857–61.
17.
Mai S, Welzel G, Ottstadt M, Lohr F, Severa S, Prigge ES, et al. Prognostic Relevance of HPV Infection and p16 Overexpression in Squamous Cell Anal Cancer.
Int J Radiat Oncol Biol Phys
. 2015 Nov;93(4):819–27.
18.
Wiwanitkit V. Urinary bladder carcinoma and human papilloma virus infection, an appraisal of risk.
Asian Pac J Cancer Prev
. 2005 Apr-Jun;6(2):217–8.
19.
Li N, Yang L, Zhang Y, Zhao P, Zheng T, Dai M. Human papillomavirus infection and bladder cancer risk: a meta-analysis.
J Infect Dis
. 2011 Jul;204(2):217–23.
20.
Jimenez-Pacheco A, Exposito-Ruiz M, Arrabal-Polo MA, Lopez-Luque AJ. Meta-analysis of studies analyzing the role of human papillomavirus in the development of bladder carcinoma.
Korean J Urol
. 2012 Apr;53(4):240–7.
21.
Aglianò AM, Gradilone A, Gazzaniga P, Napolitano M, Vercillo R, Albonici L, et al. High frequency of human papillomavirus detection in urinary bladder cancer.
Urol Int
. 1994;53(3):125–9.
22.
Gilbert MT, Haselkorn T, Bunce M, et al. The isolation of nucleic acids from fixed, paraffin-embedded tissues-which methods are useful when?
PLoS One
. 2007 Jun 20;2(6):e537.
23.
Ben Selma W, Ziadi S, Ben Gacem R, Amara K, Ksiaa F, Hachana M, et al. Investigation of human papillomavirus in bladder cancer in a series of Tunisian patients.
Pathol Res Pract
. 2010 Nov;206(11):740–3.
24.
Chang F, Lipponen P, Tervahauta A, Syrjänen S, Syrjänen K. Transitional cell carcinoma of the bladder: failure to demonstrate human papillomavirus deoxyribonucleic acid by in situ hybridization and polymerase chain reaction.
J Urol
. 1994 Nov;152(5 Pt 1):1429–33.
25.
Knowles MA. Human papillomavirus sequences are not detectable by Southern blotting or general primer-mediated polymerase chain reaction in transitional cell tumours of the bladder.
Urol Res
. 1992;20(4):297–301.
26.
Javier RT, Butel JS. The history of tumor virology.
Cancer Res
. 2008 Oct;68(19):7693–706.
27.
Tanzi E, Bianchi S, Fasolo MM, Frati ER, Mazza F, Martinelli M, et al. High performance of a new PCR-based urine assay for HPV-DNA detection and genotyping.
J Med Virol
. 2013 Jan;85(1):91–8.
28.
Cai T, Mazzoli S, Meacci F, Nesi G, Geppetti P, Malossini G, et al. Human papillomavirus and non-muscle invasive urothelial bladder cancer: potential relationship from a pilot study.
Oncol Rep
. 2011 Feb;25(2):485–9.
29.
Tenti P, Zappatore R, Romagnoli S, Civardi E, Giunta P, Scelsi R, et al. p53 overexpression and human papillomavirus infection in transitional cell carcinoma of the urinary bladder: correlation with histological parameters.
J Pathol
. 1996 Jan;178(1):65–70.
30.
Dunne EF, Nielson CM, Stone KM, Markowitz LE, Giuliano AR. Prevalence of HPV infection among men: A systematic review of the literature.
J Infect Dis
. 2006 Oct;194(8):1044–57.
31.
Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, et al. Prevalence of HPV infection among females in the United States.
JAMA
. 2007 Feb;297(8):813–9.
32.
Petignat P, Faltin D, Goffin F, Billieux MH, Stucki D, Sporri S, et al. Age-related performance of human papillomavirus testing used as an adjunct to cytology for cervical carcinoma screening in a population with a low incidence of cervical carcinoma.
Cancer
. 2005 Jun;105(3):126–32.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.